Zero: That’s the number of new HIV infections among young women and adolescent girls who took a twice-yearly preventive medicine.
Researchers tested a new formulation of pre-exposure prophylaxis, or PrEP, in a clinical trial of HIV-negative cisgender women and teens ages 16 to 25 in South Africa and Uganda. The Phase III trial compared a twice-yearly injection of the antiviral drug lenacapavir to a widely used daily PrEP pill that contains two different antiviral drugs.
.email-conversion { border: 1px solid #ffcccb; color: white; margin-top: 50px; background-image: url(“/wp-content/themes/sciencenews/client/src/images/[email protected]”); padding: 20px; clear: both; } .zephr-form-progress-bar.svelte-d78fa2{width:100%;border:0;border-radius:20px;margin-top:10px}.zephr-form-progress-bar.svelte-d78fa2::-webkit-progress-bar{background-color:var(–zephr-color-background-tinted);border:0;border-radius:20px}.zephr-form-progress-bar.svelte-d78fa2::-webkit-progress-value{background-color:var(–zephr-color-text-tinted);border:0;border-radius:20px}.zephr-progress-bar-step.svelte-d78fa2{margin:auto;color:var(–zephr-color-text-tinted);font-size:var(–zf-subtext-fontSize);font-family:var(–zf-root-fontFamily);cursor:pointer}.zephr-progress-bar-step.svelte-d78fa2:first-child{margin-left:0}.zephr-progress-bar-step.svelte-d78fa2:last-child{margin-right:0}.zephr-progress-bar-step.disabled.svelte-d78fa2{cursor:default} .zephr-form-button-top-margin.svelte-1eqnyqe{margin-top:20px}.zephr-form-button.svelte-1eqnyqe{padding:0 20px;text-decoration:none;text-transform:capitalize;border-radius:calc(var(–zephr-button-borderRadius) *→ Continue reading at Science News